Cited 0 times in

Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl JM, and Ay C

Authors
 A Passaro  ;  J Wang  ;  S Shah  ;  J M Bauml  ;  R G Campelo  ;  B C Cho 
Citation
 ANNALS OF ONCOLOGY, Vol.35(3) : 328-329, 2024-03 
Journal Title
ANNALS OF ONCOLOGY
ISSN
 0923-7534 
Issue Date
2024-03
Keywords
Acrylamides* ; Aniline Compounds / therapeutic use ; Antibodies, Bispecific* ; Carcinoma, Non-Small-Cell Lung* / drug therapy ; Carcinoma, Non-Small-Cell Lung* / genetics ; Disease Progression ; ErbB Receptors / genetics ; Humans ; Indoles* ; Lung Neoplasms* / drug therapy ; Lung Neoplasms* / genetics ; Morpholines* ; Mutation ; Protein Kinase Inhibitors / therapeutic use ; Pyrazoles* ; Pyrimidines*
Full Text
https://www.sciencedirect.com/science/article/pii/S0923753423050810
DOI
38029840
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/200572
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links